Welcome to our dedicated page for Alector news (Ticker: ALEC), a resource for investors and traders seeking the latest updates and insights on Alector stock.
Alector, Inc. develops clinical-stage biotechnology programs for neurodegenerative diseases, using genetics, immunology and neuroscience to pursue therapies that remove toxic proteins, replace missing proteins and restore immune and nerve cell function. News about ALEC commonly covers the Alector Brain Carrier (ABC) blood-brain barrier platform and ABC-enabled programs across antibodies, enzymes and siRNA.
Company updates focus on Alzheimer’s disease, Parkinson’s disease, Lewy body dementia, frontotemporal dementia and other tauopathies, including candidates such as AL137, AL050 and AL064/AL164, as well as prior clinical programs including nivisnebart and latozinemab. Recurring announcements also include financial results, cash runway commentary, clinical trial results or discontinuations, research pipeline progress, investor conference participation and executive leadership changes.
Alector (Nasdaq: ALEC) reported Q1 2026 results and a business update on May 7, 2026. Cash, cash equivalents, and investments were $206.5 million as of March 31, 2026, which management expects will fund operations at least through 2027. The company advanced its Alector Brain Carrier (ABC) platform across antibodies, enzymes, and siRNA, highlighted IND-targeting timelines (AL037/AL137 targeted for Q1 2027), ongoing preclinical progress for AL050 and AL164, and discontinuation of the PROGRESS-AD Phase 2 nivisnebart trial after a prespecified interim futility analysis.
Q1 financials: collaboration revenue $1.0M, R&D $17.9M, G&A $8.1M, net loss $22.9M (≈$0.21/share).
Alector (Nasdaq: ALEC) will discontinue the Phase 2 PROGRESS-AD trial of nivisnebart (AL101/GSK4527226) in early Alzheimer’s disease after an independent data monitoring committee found the trial unlikely to meet its primary endpoint.
Alector and GSK will inform participants; full results will be shared at a future medical meeting. Alector says it will continue advancing multiple ABC-enabled programs with IND targets in 2027.
Alector (NASDAQ: ALEC) reported Q4 and full-year 2025 results and provided an update on its ABC brain-delivery platform and multiple preclinical and clinical programs. Cash, cash equivalents and investments totaled $256.0 million as of December 31, 2025, which management expects will fund operations at least through 2027.
Key program milestones include an independent interim futility analysis for PROGRESS-AD (nivisnebart/AL101) planned in 1H 2026 and IND timelines for ABC-enabled candidates AL137, AL050, and AL064 targeting 2026–2027 filings.
Alector (Nasdaq: ALEC) said management will present at the TD Cowen 46th Annual Health Care Conference on March 3, 2026 at 3:10 PM ET. A live webcast will be available on the company’s Investors “Events & Presentations” page, with a replay accessible for 90 days.
Alector (Nasdaq: ALEC) appointed Neil Berkley as Chief Financial Officer effective December 10, 2025. Berkley has served as Chief Business Officer since March 2024 and as Interim CFO since June 2025, and will continue to serve as CBO.
He brings more than two decades of experience in corporate strategy, finance, business development, fundraising, and operations across large pharma and biotech. Since joining in 2024 he helped advance strategic priorities, partnerships, and value-creation initiatives while supporting the company’s pipeline and ABC-enabled programs.
Alector (Nasdaq: ALEC) announced that management will participate in a fireside chat at the Bank of America CNS Therapeutics Conference on Monday, December 8, 2025 at 2:25 pm ET. A live webcast will be available on the company’s Investors > Events & Presentations page at http://investors.alector.com. A replay will be posted on the Alector website and will remain available for 90 days following the event.
Alector (Nasdaq: ALEC) reported Q3 2025 results and a business update highlighting advancement of its Alector Brain Carrier (ABC) platform and multiple IND‑enabling programs. Cash, cash equivalents, and investments were $291.1 million as of September 30, 2025, providing runway through 2027. Lead ABC candidates AL137 (anti‑amyloid beta) and AL050 (GCase ERT) are advancing toward IND‑enabling studies with IND targets in 2026 and 2027. PROGRESS‑AD Phase 2 interim analysis for nivisnebart (AL101) is planned for 1H 2026. The company reported Q3 collaboration revenue of $3.3M, R&D expense of $29.4M, G&A of $11.5M, and net loss of $34.7M. Latozinemab Phase 3 INFRONT‑3 did not show clinical benefit and related studies will be discontinued.
Alector (Nasdaq: ALEC) reported topline Phase 3 INFRONT-3 results for latozinemab (AL001) in FTD-GRN on Oct 21, 2025: the trial did not meet its clinical co-primary endpoint (CDR plus NACC FTLD-SB) at 96 weeks although it achieved a statistically significant effect on the biomarker co-primary of plasma progranulin (PGRN).
Secondary/exploratory endpoints including fluid biomarkers and vMRI showed no treatment-related effects. The open-label extension and continuation study will be discontinued. Preliminary safety data show no major safety signals. Alector is cutting ~49% of its workforce, expects ~$291.1M cash as of Sep 30, 2025 providing runway through 2027, and plans IND submissions for ABC-enabled AL137 (2026) and AL050 (2027).
Alector (Nasdaq: ALEC) announced a virtual R&D event scheduled for September 22, 2025, focusing on their progranulin (PGRN) franchise and Alector Brain Carrier (ABC) programs. The presentation will highlight two key clinical programs: latozinemab, in Phase 3 trials for frontotemporal dementia, and AL101, in Phase 2 trials for early Alzheimer's disease.
The event will also showcase preclinical data from their ABC-enabled programs, including a brain-penetrant anti-amyloid beta antibody for Alzheimer's and a GCase-enzyme replacement therapy for Parkinson's disease. Additionally, updates on ABC-enabled siRNA programs will be presented, demonstrating the platform's versatility in treating neurodegenerative diseases.
Alector (NASDAQ: ALEC), a late-stage clinical biotechnology company specializing in neurodegeneration therapies, has announced its participation in three upcoming healthcare investor conferences in September 2025.
The company will present at the Cantor Global Healthcare Conference on September 4 at 3:55 p.m. ET, the Morgan Stanley Global Healthcare Conference on September 8 at 10:00 a.m. ET, and the H.C. Wainwright Global Investment Conference on September 9 at 1:30 p.m. ET. All presentations will be available via webcast on Alector's investor relations website, with replays accessible for 90 days.